Priced-In Pessimism

Priced-In Pessimism

At $65.87 Booz Allen trades at about 10.5x consensus FY2027 earnings and an ~11% free-cash-flow yield, but on management's clean $5.90 earnings base the multiple is ~11x, and stripping a non-repeatable $207 million billed-receivables release leaves underlying FY2026 free cash flow nearer $750 million than the reported $951 million — so the discount to its ~20x pre-2023 norm is measured against tax- and working-capital-flattered headline figures.

On the clean $5.90 base the forward P/E is ~11x rather than 10.5x, and on ~$750 million of underlying free cash flow the yield is ~9% rather than the ~11.8% the reported figure implies; normalising both eases the roughly negative-2% perpetual decline the headline price embeds and halves the apparent discount to the ~20x pre-2023 norm. The strongest fact on the other side sits in the same cohort: Leidos (9.6x) and Maximus (9.5x) carry the same multiple, so the market is repricing a Civil-exposed cohort rather than mispricing one name.

What the price implies

The de-rating this report opened with has left a specific set of numbers on the tape. At $65.87 and about 120 million shares, the equity is worth roughly $8.0 billion; adding $3.2 billion of net debt puts enterprise value near $11.2 billion. Against FY2026 results and FY2027 guidance, that produces the following.

Sources: derived from the $65.87 close (as reported) and FY2027 guidance — revenue $11.2–11.7B, adjusted EBITDA $1,240–1,290M, adjusted EPS $6.00–6.35, free cash flow $825–925M [1]; the $0.59 quarterly dividend annualised [2].

The forward earnings yield is about 9.5%. A durable way to read that, without narrating what anyone must believe, is to solve for the growth the price embeds. Capitalising the midpoint of FY2027 free-cash-flow guidance — roughly $875 million [3] — at a 9% required return implies a no-growth value near $9.7 billion, modestly above the $8.0 billion of equity outstanding. Turned around, the current price is consistent with free cash flow shrinking about 2% a year in perpetuity (nearer 1% at a 10% discount rate, 3% at 8%).

That is the core of the "how much pessimism is priced in" question: on its headline figures, the market is paying for a business it expects to stagnate or gently decline, against a backdrop of a record $38.2 billion backlog, 1.1x book-to-bill, and $951 million of reported free cash flow [4]. The rest of this chapter tests whether those headline figures deserve to be taken at face value.

The multiple in context

Booz Allen's own history frames how far the multiple has travelled. At each fiscal-year close, trailing earnings and the share price imply the following P/E — the FY2023 spike is an artefact of that year's 4.8% margin trough, not a re-rating.

Source: derived from fiscal-year-end closing prices (as reported) and reported diluted EPS, FY2019–FY2026 10-Ks; at the $65.87 close on July 24, 2026 the trailing multiple is about 9.5x.

Setting the FY2023 earnings-trough distortion aside, Booz Allen spent the years before its 2024 peak in an 18–20x band and briefly reached the low-30s in the AI-and-defense enthusiasm of FY2024. At 9.5x trailing today, the multiple is roughly half its pre-2023 norm — a larger cut than the 9% decline in FY2026 net income, which is the arithmetic behind the fallen-star framing set out in Fallen Compounder.

The peer set tempers that. Ranking the named federal-services rivals on trailing earnings, Booz Allen sits at the bottom of the group — but not alone.

Source: derived from company financial filings (latest reported net income) and market capitalisations as reported; trailing basis, differing fiscal year-ends.

The peer median is about 14.5x, so Booz Allen does carry a discount to the group. But the two names beside it — Leidos and Maximus — are precisely the peers most exposed to federal-civilian and health-agency work, the same DOGE-era retrenchment examined in Federal Demand. The premium names, Parsons and CACI, are weighted toward defense, intelligence, and infrastructure. The market has not singled out Booz Allen; it has re-rated a Civil-exposed cohort together. Whether that is collective mispricing or a shared, rational read on a smaller civilian market is the question the discount cannot settle on its own.

The fair counter-case

A value lens naturally leads with the discount. The discipline is to give the opposite reading — that the low multiple is deserved — its strongest, fairest form. Four facts do the work, and each is on the primary record.

The headline earnings are tax-flattered. Operating income fell 25% in FY2026, from $1,370 million to $1,033 million [5]; net income fell only 9% because the effective tax rate collapsed to 1.3%, an $11 million charge against $284 million a year earlier [6]. On management's own clean base — the bridge detailed in Financials and Estimates — underlying earnings power is nearer $5.90 than the $6.90 GAAP figure. Recompute the forward multiple on a normalised numerator and 10.5x becomes closer to 11x, a good deal less arresting.

The headline cash is working-capital-flattered. FY2026 free cash flow of $951 million included a $207 million release of accounts receivable as revenue shrank [7] — a one-time benefit of a declining top line, not a repeatable source. Management's own FY2027 guidance implies the same: $825–925 million of free cash flow after $220 million of capex, $105 million of it for a new headquarters [8]. The ~11% FCF yield is real, but it rests on a mid-$800-million run-rate, not the flattered $951 million.

The backlog is thinner than the headline. Of the record $38.2 billion, only $4.3 billion — 11% — is funded; $10.2 billion is unfunded and $23.7 billion is priced options that require future exercise and appropriations [9]. Backlog is genuine coverage, but the portion the government has actually committed money to is a small slice of it, and Federal Demand documented Civil recompetes returning with shorter terms and smaller scope — a high win rate buying less revenue.

Source: FY2026 Annual Report (Form 10-K), backlog table — total $38,187M [10].

There is no asset floor. As Financials and Estimates established, tangible equity is about negative $1.8 billion after years of buybacks. The value here is entirely the forward earnings stream; if that stream rebases lower, there is no book value to catch the price. And the risk factors name the mechanism plainly — spending caps, shifting budget priorities, and program delays can cut new awards across defense, intelligence, and civil work [11], while the shift toward fixed-price contracting raises the risk of cost overruns on a book that was 59% cost-reimbursable [12].

Taken together, the fair impairment case is not that the business is broken — it is that a cheap multiple can be the correct price for a franchise whose addressable civilian market is smaller than it was, whose headline earnings and cash are running a little hot, and whose whole cohort de-rated on the same read. Cheap names can stay cheap through a multi-year rebasing.

Two readings of the same facts

Each row below is a shared fact from the record, read two ways, with the evidence that would tip it.

Sources: FY2027 guidance [13]; backlog composition [14]; operating income [15]; effective tax rate [16]; receivables release [17].

Where the evidence leaves the read: at about 10.5x forward earnings and a roughly negative-2% implied perpetual growth rate, the quote already discounts a mild secular impairment, so even a no-growth base leaves modest upside — the arithmetic tilts toward the trough interpretation the sell-side broadly shares, with a mean target of about $79 against the $65.87 quote (consensus estimates). The honest weight on the other side is that the discount is a cohort discount, not an idiosyncratic one, and that it sits on tax- and working-capital-flattered figures; normalise both and the fairer anchor is closer to 11x clean earnings, where the margin of safety is real but thinner than the headline yield suggests. The case is most sensitive to the direction of Civil revenue — whether it inflects sequentially positive in the second half of FY2027; until it does, the impairment reading keeps its claim on the discount.